Recently, a clinical trial testing dupilumab, a monoclonal antibody targeting interleukin 13(IL-13) and interleukin 4 (IL-4) pathways, was able to reduce type-2 inflammation and exacerbations and increase lung function in COPD patients with a high eosinophil count when used alongside inhaled triple therapy [129,134]. Here, IL4 is linked to chronic obstructive pulmonary disease.